Professor Jeong In-ha of Korea University Ansan Hospital wins the Best Study Award of the Korean Diabetes Association
Oct 31, 2024
Professor Jeong In-ha of the Department of Endocrinology at Korea University Ansan Hospital won the best presentation at the international conference of the Korean Diabetes Association '2024 KDA Scientific Meeting: 14th International Congress of Diabetics and Metabolism (ICDM2024)'.
Professor Jeong was honored with a research presentation on the improvement of blood sugar control by dulaglutide and the association of changes in leptin and ovestatin levels in type 2 diabetes patients' (Improvement of glycemic control by dulaglutide is associated with changes in leptin and ovestatin levels with type 2 diabetes melitus, corresponding author Professor Yoo Ji-hee of the Department of Endocrinology at Korea Ansan Hospital).
Until now, the GLP-1 receptor agonist dulaglutide, a diabetes treatment, has relatively few studies on gastrointestinal hormones compared to other GLP-1 receptor agonists.
In response, Professor Chung analyzed the association between improved blood sugar control and changes in hormone levels such as leptin and ovestatin after dulaglutide administration for 24 weeks in patients with type 2 diabetes.
Leptin is a hormone that suppresses appetite so that the brain feels full and no longer eats food, but in diabetics and obese people, the level of leptin increases abnormally, resulting in dysfunction 'leptin resistance'. As a result, you do not feel full, causing overeating. Obestatin is also known as a hormone related to appetite suppression.
Studies have shown that dulaglutide reduced glycated hemoglobin (HbA1c) and improved the function of pancreatic beta cells to make insulin. The study also confirmed for the first time that dulaglutide, like other GLP-1 receptor agonists, can contribute to blood sugar control by lowering leptin levels. In particular, it also drew attention from academia by revealing a new fact that an increase in ovestatin levels is closely related to the blood sugar improvement effect of GLP-1 receptor agonists.
Professor Jeong stated that "the administration of dulaglutide appears to have a significant impact on the improvement of blood sugar in patients with type 2 diabetes, with the decrease of leptin levels along with the improvement of insulin resistance as well as the increase of ovestatin levels through the administration of dulaglutide" and "Planning to continue further studies to identify the characteristics of patients who respond particularly effectively to GLP-1 receptor agonists in patients with type 2 diabetes"
Professor Jeong was honored with a research presentation on the improvement of blood sugar control by dulaglutide and the association of changes in leptin and ovestatin levels in type 2 diabetes patients' (Improvement of glycemic control by dulaglutide is associated with changes in leptin and ovestatin levels with type 2 diabetes melitus, corresponding author Professor Yoo Ji-hee of the Department of Endocrinology at Korea Ansan Hospital).
Until now, the GLP-1 receptor agonist dulaglutide, a diabetes treatment, has relatively few studies on gastrointestinal hormones compared to other GLP-1 receptor agonists.
In response, Professor Chung analyzed the association between improved blood sugar control and changes in hormone levels such as leptin and ovestatin after dulaglutide administration for 24 weeks in patients with type 2 diabetes.
Leptin is a hormone that suppresses appetite so that the brain feels full and no longer eats food, but in diabetics and obese people, the level of leptin increases abnormally, resulting in dysfunction 'leptin resistance'. As a result, you do not feel full, causing overeating. Obestatin is also known as a hormone related to appetite suppression.
Studies have shown that dulaglutide reduced glycated hemoglobin (HbA1c) and improved the function of pancreatic beta cells to make insulin. The study also confirmed for the first time that dulaglutide, like other GLP-1 receptor agonists, can contribute to blood sugar control by lowering leptin levels. In particular, it also drew attention from academia by revealing a new fact that an increase in ovestatin levels is closely related to the blood sugar improvement effect of GLP-1 receptor agonists.
Professor Jeong stated that "the administration of dulaglutide appears to have a significant impact on the improvement of blood sugar in patients with type 2 diabetes, with the decrease of leptin levels along with the improvement of insulin resistance as well as the increase of ovestatin levels through the administration of dulaglutide" and "Planning to continue further studies to identify the characteristics of patients who respond particularly effectively to GLP-1 receptor agonists in patients with type 2 diabetes"
|
bellho@sportschosun.com
